{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:48:06Z","timestamp":1792399686529,"version":"4.4.0"},"reference-count":51,"publisher":"Oxford University Press (OUP)","issue":"10","license":[{"start":{"date-parts":[[2026,9,26]],"date-time":"2026-09-26T00:00:00Z","timestamp":1790380800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100006108","name":"National Center for Advancing Translational Sciences","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006108","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UL1 TR002535"],"award-info":[{"award-number":["UL1 TR002535"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["UM1 TR004399"],"award-info":[{"award-number":["UM1 TR004399"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K12 HD113190"],"award-info":[{"award-number":["K12 HD113190"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01 AI170298"],"award-info":[{"award-number":["R01 AI170298"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["K24AI196322"],"award-info":[{"award-number":["K24AI196322"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001130","name":"Gerber Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001130","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Novice Research"},{"name":"Children's Hospital Colorado Research Scholar Award"},{"name":"Eunice Kennedy Shriver National Institute of Child Health"},{"DOI":"10.13039\/100000060","name":"National Institute of Allergy and Infectious Diseases","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000060","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100000925","name":"National Health and Medical Research Council Investigator","doi-asserted-by":"publisher","award":["GNT2033626"],"award-info":[{"award-number":["GNT2033626"]}],"id":[{"id":"10.13039\/501100000925","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,9,29]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Cephalexin is increasingly used as initial and oral transition therapy for severe infections, but optimal dosing in this setting remains uncertain.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Four cephalexin pharmacokinetic (PK) datasets spanning preterm neonates through young adults were pooled to develop a unified population PK model. Simulations estimated probability of target attainment (PTA) and cumulative fractional response (CFR, target attainment weighted across the pathogen MIC distribution) across fT &amp;gt; MIC targets (free drug time above the minimum inhibitory concentration), MIC distributions for methicillin-susceptible Staphylococcus aureus (MSSA) and Enterobacterales, and multiple dosing regimens.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Seventy-one subjects (age 9 days\u201329 years) contributed 360 plasma samples, best described by a 1-compartment model with first-order absorption and lag time. Apparent volume and clearance scaled with fat-free mass, and clearance increased with postmenstrual age. Absorption was slower in neonates. Cephalexin 25\u2005mg\/kg\/dose, maximum 1000\u2005mg, every 8\u2005hours, achieved 1-log kill targets for MSSA (PTA \u2265 98% for 35% fT &amp;gt; MIC at MIC = 4\u2005mg\/L); every 6-hour dosing was needed at MIC = 8\u2005mg\/L. For Enterobacterales, a 60% fT &amp;gt; MIC target was achieved only in infants &amp;lt; 2 months. However, higher-dose regimens (37.5\u201350\u2005mg\/kg, maximum 1500\u2005mg, every 6\u2005hours) achieved CFRs &amp;gt; 90% for 40%\u201350% fT &amp;gt; MIC targets when cefazolin MICs were \u22642\u2005mg\/L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Cephalexin PK varies with age but is well-captured by a unified size- and maturation-scaled model. These data support dosing within the FDA-approved range for systemic MSSA infections. Higher-dose regimens are necessary for adequate target attainment against Enterobacterales. Appropriately dosed cephalexin represents a viable option for selected severe infections, including oral transition therapy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/ofid\/ofag611","type":"journal-article","created":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T11:18:15Z","timestamp":1790335095000},"source":"Crossref","is-referenced-by-count":0,"title":["Cephalexin Model-Informed Dosing Recommendations for Severe Infections: A Pooled Pharmacokinetic Analysis From Infancy to Adulthood"],"prefix":"10.1093","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-5486-0522","authenticated-orcid":false,"given":"Andrew S","family":"Haynes","sequence":"first","affiliation":[{"name":"Department of Pediatrics, Section of Pediatric Infectious Diseases, Children's Hospital Colorado , Aurora, Colorado ,","place":["USA"]},{"name":"School of Medicine, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5522-5686","authenticated-orcid":false,"given":"Daniel","family":"Gonzalez","sequence":"additional","affiliation":[{"name":"Division of Clinical Pharmacology, Department of Medicine, Duke University School of Medicine , Durham, North Carolina ,","place":["USA"]},{"name":"Duke Clinical Research Institute , Durham, North Carolina ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5830-3491","authenticated-orcid":false,"given":"Kevin","family":"Messacar","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Section of Pediatric Infectious Diseases, Children's Hospital Colorado , Aurora, Colorado ,","place":["USA"]},{"name":"School of Medicine, University of Colorado Anschutz Medical Campus , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Julie","family":"Autmizguine","sequence":"additional","affiliation":[{"name":"Department of Pediatrics, Section of Pediatric Infectious Diseases, Sainte-Justine University Hospital , Montreal ,","place":["Canada"]},{"name":"Azrieli Sainte-Justine Research Center , Montr\u00e9al ,","place":["Canada"]},{"name":"Department of Pharmacology and Physiology, Universit\u00e9 de Montr\u00e9al , Montr\u00e9al ,","place":["Canada"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4016-8986","authenticated-orcid":false,"given":"Amanda","family":"Gwee","sequence":"additional","affiliation":[{"name":"Antimicrobials Group, Murdoch Children's Research Institute , Parkville, Victoria ,","place":["Australia"]},{"name":"Department of Paediatrics, University of Melbourne , Parkville, Victoria ,","place":["Australia"]},{"name":"Department of General Medicine and Infectious Diseases, Royal Children's Hospital Melbourne , Parkville, Victoria ,","place":["Australia"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5905-5178","authenticated-orcid":false,"given":"Richard","family":"Everts","sequence":"additional","affiliation":[{"name":"Infectious Disease Service, Nelson Bays Primary Health , Nelson ,","place":["New Zealand"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1200-8494","authenticated-orcid":false,"given":"Peter","family":"Anderson","sequence":"additional","affiliation":[{"name":"Department of Pharmaceutical Sciences, University of Colorado Skaggs School of Pharmacy and Pharmaceutical Sciences , Aurora, Colorado ,","place":["USA"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2026,9,26]]},"reference":[{"key":"2026101904315757500_ofag611-B1","doi-asserted-by":"crossref","first-page":"510","DOI":"10.1542\/pir.34.11.510","article-title":"Cephem antibiotics: wise use today preserves cure for tomorrow","volume":"34","author":"Parker","year":"2013","journal-title":"Pediatr Rev"},{"key":"2026101904315757500_ofag611-B2","author":"Pragma Pharmaceuticals LLC"},{"key":"2026101904315757500_ofag611-B3"},{"key":"2026101904315757500_ofag611-B4"},{"key":"2026101904315757500_ofag611-B5","volume-title":"Clinical pathway","author":"Hogeland","year":"2025"},{"key":"2026101904315757500_ofag611-B6","author":"Hauger"},{"key":"2026101904315757500_ofag611-B7"},{"key":"2026101904315757500_ofag611-B8","author":"Gyura"},{"key":"2026101904315757500_ofag611-B9","doi-asserted-by":"crossref","first-page":"788","DOI":"10.1097\/INF.0000000000001635","article-title":"Bone and joint infections","volume":"36","author":"Saavedra-Lozano","year":"2017","journal-title":"Pediatr Infect Dis J"},{"key":"2026101904315757500_ofag611-B10","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1093\/jpids\/piab027","article-title":"Clinical practice guideline by the pediatric infectious diseases society and the Infectious Diseases Society of America: 2021 guideline on diagnosis and management of acute hematogenous osteomyelitis in pediatrics","volume":"10","author":"Woods","year":"2021","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2026101904315757500_ofag611-B11","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1097\/INF.0b013e3182a222a6","article-title":"Pharmacokinetics and pharmacodynamics of oral cephalexin in children with osteoarticular infections","volume":"32","author":"Autmizguine","year":"2013","journal-title":"Pediatr Infect Dis J"},{"key":"2026101904315757500_ofag611-B12","doi-asserted-by":"crossref","first-page":"e0018224","DOI":"10.1128\/aac.00182-24","article-title":"Cefadroxil and cephalexin pharmacokinetics and pharmacodynamics in children with musculoskeletal infections","volume":"68","author":"Haynes","year":"2024","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101904315757500_ofag611-B13","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1136\/adc.48.2.147","article-title":"Absorption and excretion of cephalexin by the newborn infant","volume":"48","author":"Boothman","year":"1973","journal-title":"Arch Dis Child"},{"key":"2026101904315757500_ofag611-B14","doi-asserted-by":"crossref","first-page":"2103","DOI":"10.1055\/s-0028-1108787","article-title":"Pharmacokinetics of cephalexin in adults and children","volume":"95","author":"Simon","year":"1970","journal-title":"Dtsch Med Wochenschr"},{"key":"2026101904315757500_ofag611-B15","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1097\/INF.0000000000002646","article-title":"Twice- and thrice-daily cephalexin dosing for Staphylococcus aureus infections in children","volume":"39","author":"Gwee","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"2026101904315757500_ofag611-B16","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1111\/j.1469-0691.2011.03643.x","article-title":"Clindamycin vs. First-generation cephalosporins for acute osteoarticular infections of childhood--a prospective quasi-randomized controlled trial","volume":"18","author":"Peltola","year":"2012","journal-title":"Clin Microbiol Infect"},{"key":"2026101904315757500_ofag611-B17","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1097\/INF.0b013e3181f55a89","article-title":"Short- versus long-term antimicrobial treatment for acute hematogenous osteomyelitis of childhood: prospective, randomized trial on 131 culture-positive cases","volume":"29","author":"Peltola","year":"2010","journal-title":"Pediatr Infect Dis J"},{"key":"2026101904315757500_ofag611-B18","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1093\/jac\/dkae423","article-title":"Efficacy and tolerability of high-dose cefalexin 45 mg\/kg\/dose (maximum 1.5 g) three times daily in children with bone and joint infections","volume":"80","author":"Hikmat","year":"2025","journal-title":"J Antimicrob Chemother"},{"key":"2026101904315757500_ofag611-B19"},{"key":"2026101904315757500_ofag611-B20"},{"key":"2026101904315757500_ofag611-B21","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1093\/jpids\/piad089","article-title":"Clinical practice guideline by the pediatric infectious diseases society (PIDS) and the Infectious Diseases Society of America (IDSA): 2023 guideline on diagnosis and management of acute bacterial arthritis in pediatrics","volume":"13","author":"Woods","year":"2024","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2026101904315757500_ofag611-B22","doi-asserted-by":"crossref","first-page":"e332","DOI":"10.1097\/PEC.0000000000001342","article-title":"Improving antibiotic prescribing for children with urinary tract infection in emergency and urgent care settings","volume":"36","author":"Poole","year":"2020","journal-title":"Pediatr Emerg Care"},{"key":"2026101904315757500_ofag611-B23","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1001\/jamapediatrics.2023.1979","article-title":"Short-course therapy for urinary tract infections in children: the SCOUT randomized clinical trial","volume":"177","author":"Zaoutis","year":"2023","journal-title":"JAMA Pediatr"},{"key":"2026101904315757500_ofag611-B24","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.1093\/ofid\/ofv133.1124","article-title":"Cephalexin for outpatient urinary tract infections in children","volume":"2","author":"Beus","year":"2015","journal-title":"Open Forum Infect Dis"},{"key":"2026101904315757500_ofag611-B25","first-page":"829","article-title":"An ambulatory antimicrobial stewardship initiative to improve diagnosis and treatment of urinary tract infections in children","volume":"45","author":"Walters","year":"2019","journal-title":"Jt Comm J Qual Patient Saf"},{"key":"2026101904315757500_ofag611-B26","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1177\/00099228221112055","article-title":"Retrospective comparison of cefdinir, cephalexin, and sulfamethoxazole-trimethoprim in the treatment of outpatient pediatric urinary tract infections","volume":"62","author":"Cardinale","year":"2023","journal-title":"Clin Pediatr (Phila)"},{"key":"2026101904315757500_ofag611-B27","doi-asserted-by":"crossref","first-page":"e2352314","DOI":"10.1001\/jamanetworkopen.2023.52314","article-title":"Early switch from intravenous to oral antibiotics for patients with uncomplicated gram-negative bacteremia","volume":"7","author":"Tingsgard","year":"2024","journal-title":"JAMA Netw Open"},{"key":"2026101904315757500_ofag611-B28","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.cmi.2023.10.014","article-title":"Switch to oral antibiotics in gram-negative bacteraemia: a randomized, open-label, clinical trial","volume":"30","author":"Omrani","year":"2024","journal-title":"Clin Microbiol Infect"},{"key":"2026101904315757500_ofag611-B29","doi-asserted-by":"crossref","first-page":"e2020166","DOI":"10.1001\/jamanetworkopen.2020.20166","article-title":"Oral beta-lactam antibiotics vs fluoroquinolones or trimethoprim-sulfamethoxazole for definitive treatment of enterobacterales bacteremia from a urine source","volume":"3","author":"Sutton","year":"2020","journal-title":"JAMA Netw Open"},{"key":"2026101904315757500_ofag611-B30","doi-asserted-by":"crossref","first-page":"ofad657","DOI":"10.1093\/ofid\/ofad657","article-title":"Oral beta-lactams, fluoroquinolones, or trimethoprim-sulfamethoxazole for definitive treatment of uncomplicated Escherichia coli or Klebsiella Species bacteremia from a urinary tract source","volume":"11","author":"Alzaidi","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026101904315757500_ofag611-B31","doi-asserted-by":"crossref","first-page":"e0170425","DOI":"10.1128\/spectrum.01704-25","article-title":"Effect of oral beta-lactam dosing on outcomes of bacteremic gram-negative urinary tract infections: a real-world analysis","volume":"14","author":"May","year":"2026","journal-title":"Microbiol Spectr"},{"key":"2026101904315757500_ofag611-B32","doi-asserted-by":"crossref","first-page":"e148","DOI":"10.1017\/ash.2023.435","article-title":"Outcomes of high-dose oral beta-lactam definitive therapy compared to fluoroquinolone or trimethoprim-sulfamethoxazole oral therapy for bacteremia secondary to a urinary tract infection","volume":"3","author":"Geyer","year":"2023","journal-title":"Antimicrob Steward Healthc Epidemiol"},{"key":"2026101904315757500_ofag611-B33","doi-asserted-by":"crossref","first-page":"ofz364","DOI":"10.1093\/ofid\/ofz364","article-title":"Oral fluoroquinolone or trimethoprim-sulfamethoxazole vs. \u03b2-lactams as step-down therapy for Enterobacteriaceae bacteremia: systematic review and meta-analysis","volume":"6","author":"Punjabi","year":"2019","journal-title":"Open Forum Infect Dis"},{"key":"2026101904315757500_ofag611-B34","doi-asserted-by":"crossref","first-page":"ofae193","DOI":"10.1093\/ofid\/ofae193","article-title":"Real-world effectiveness of intravenous and oral antibiotic stepdown strategies for gram-negative complicated urinary tract infection with bacteremia","volume":"11","author":"Veillette","year":"2024","journal-title":"Open Forum Infect Dis"},{"key":"2026101904315757500_ofag611-B35","doi-asserted-by":"crossref","first-page":"piaf088","DOI":"10.1093\/jpids\/piaf088","article-title":"Oral cephalexin population pharmacokinetics and target attainment analysis in infants 7-60 days old","volume":"14","author":"Haynes","year":"2025","journal-title":"J Pediatric Infect Dis Soc"},{"key":"2026101904315757500_ofag611-B36","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.jinf.2021.05.037","article-title":"Probenecid effects on cephalexin pharmacokinetics and pharmacodynamics in healthy volunteers","volume":"83","author":"Everts","year":"2021","journal-title":"J Infect"},{"key":"2026101904315757500_ofag611-B37","author":"Andes"},{"key":"2026101904315757500_ofag611-B38","doi-asserted-by":"crossref","first-page":"ofad500-2169","DOI":"10.1093\/ofid\/ofad500.2169","article-title":"2552. comparative pharmacodynamic evaluation of commonly utilized, oral, 1st - 3rd generation cephalosporins against S. aureus and E. coli in the mouse thigh infection model","volume":"10","author":"Lepak","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026101904315757500_ofag611-B39","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1086\/516284","article-title":"Pharmacokinetic\/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men","volume":"26","author":"Craig","year":"1998","journal-title":"Clin Infect Dis"},{"key":"2026101904315757500_ofag611-B40","doi-asserted-by":"crossref","first-page":"1577","DOI":"10.1128\/AAC.01590-12","article-title":"In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice","volume":"57","author":"Craig","year":"2013","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101904315757500_ofag611-B41","doi-asserted-by":"crossref","first-page":"S16","DOI":"10.1002\/jhm.869","article-title":"Use of pharmacodynamic principles to inform beta-lactam dosing: \u201cS\u201d does not always mean success","volume":"6","author":"Lodise","year":"2011","journal-title":"J Hosp Med"},{"key":"2026101904315757500_ofag611-B42","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.diagmicrobio.2013.08.024","article-title":"Cefazolin as a class representative for oral cephalosporins and uncomplicated urinary tract infections caused by indicated Enterobacteriaceae","volume":"77","author":"Schuetz","year":"2013","journal-title":"Diagn Microbiol Infect Dis"},{"key":"2026101904315757500_ofag611-B43","doi-asserted-by":"crossref","first-page":"e0103922","DOI":"10.1128\/spectrum.01039-22","article-title":"Cefadroxil comparable to cephalexin: minimum inhibitory concentrations among methicillin-susceptible Staphylococcus aureus isolates from pediatric musculoskeletal infections","volume":"10","author":"Haynes","year":"2022","journal-title":"Microbiol Spectr"},{"key":"2026101904315757500_ofag611-B44","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.3390\/antibiotics12091402","article-title":"A systematic review on the clinical pharmacokinetics of cephalexin in healthy and diseased populations","volume":"12","author":"Kanan","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"2026101904315757500_ofag611-B45","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1177\/0009922806289081","article-title":"Success of short-course parenteral antibiotic therapy for acute osteomyelitis of childhood","volume":"46","author":"Bachur","year":"2007","journal-title":"Clin Pediatr (Phila)"},{"key":"2026101904315757500_ofag611-B46","doi-asserted-by":"crossref","first-page":"ofad610","DOI":"10.1093\/ofid\/ofad610","article-title":"First-generation cephalosporins for treatment of acute hematogenous osteomyelitis in children: a study of efficacy and adverse effects","volume":"10","author":"Hiskey","year":"2023","journal-title":"Open Forum Infect Dis"},{"key":"2026101904315757500_ofag611-B47","doi-asserted-by":"crossref","first-page":"523","DOI":"10.1097\/INF.0000000000002661","article-title":"Frequency of dosing of cephalexin for oral step-down therapy of pediatric osteoarticular infections caused by methicillin-sensitive Staphylococcus Aureus","volume":"39","author":"Ramchandar","year":"2020","journal-title":"Pediatr Infect Dis J"},{"key":"2026101904315757500_ofag611-B48","doi-asserted-by":"crossref","first-page":"255","DOI":"10.1097\/01241398-198208000-00004","article-title":"Benefits and risks of sequential parenteral--oral cephalosporin therapy for suppurative bone and joint infections","volume":"2","author":"Nelson","year":"1982","journal-title":"J Pediatr Orthop"},{"key":"2026101904315757500_ofag611-B49","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1128\/AAC.00433-18","article-title":"The inoculum effect in the era of multidrug resistance: minor differences in inoculum have dramatic effect on MIC determination","volume":"62","author":"Smith","year":"2018","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101904315757500_ofag611-B50","doi-asserted-by":"crossref","first-page":"e0090822","DOI":"10.1128\/aac.00908-22","article-title":"Evaluation of oral tebipenem as a step-down therapy following intravenous ertapenem against extended-spectrum beta-lactamase-producing Escherichia coli in a hollow-fiber in vitro infection model","volume":"67","author":"VanScoy","year":"2023","journal-title":"Antimicrob Agents Chemother"},{"key":"2026101904315757500_ofag611-B51","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1016\/j.ijid.2019.02.005","article-title":"Antibiotic penetration into bone and joints: an updated review","volume":"81","author":"Thabit","year":"2019","journal-title":"Int J Infect Dis"}],"container-title":["Open Forum Infectious Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/ofid\/advance-article-pdf\/doi\/10.1093\/ofid\/ofag611\/71399972\/ofag611.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/10\/ofag611\/71399972\/ofag611.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/ofid\/article-pdf\/13\/10\/ofag611\/71399972\/ofag611.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,19]],"date-time":"2026-10-19T08:32:10Z","timestamp":1792398730000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/ofid\/article\/doi\/10.1093\/ofid\/ofag611\/8836350"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,26]]},"references-count":51,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,9,29]]}},"URL":"https:\/\/doi.org\/10.1093\/ofid\/ofag611","relation":{},"ISSN":["2328-8957"],"issn-type":[{"value":"2328-8957","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,10]]},"published":{"date-parts":[[2026,9,26]]},"article-number":"ofag611"}}